# Anti Inflammatory Treatment of Hypertension

Study · id `cardio:ct-nct04740840` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04740840](<https://clinicaltrials.gov/study/NCT04740840>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04740840

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT04740840. Randomized; single masking; primary purpose treatment. Start 2010-05-01 (actual); primary completion 2012-04-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT04740840, source copy `cardio:ctgov-nct04740840-2021-02-05`, retrieved 2026-10-26)
- Started: 2010-05-01 (actual) (ClinicalTrials.gov record NCT04740840, source copy `cardio:ctgov-nct04740840-2021-02-05`, retrieved 2026-10-26)
- Primary completion: 2012-04-02 (actual) (ClinicalTrials.gov record NCT04740840, source copy `cardio:ctgov-nct04740840-2021-02-05`, retrieved 2026-10-26)
- Completion: 2015-05-02 (actual) (ClinicalTrials.gov record NCT04740840, source copy `cardio:ctgov-nct04740840-2021-02-05`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04740840-2021-02-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Anti Inflammatory Treatment of Hypertension
- Condition: Hypertension
- Intervention (Drug): Levamlodipine
- Intervention (Drug): Amlodipine
- Lead sponsor: Afﬁliated Hospital of North Sichuan Medical College
- Lead sponsor class: OTHER
- Collaborator: First Hospitals affiliated to the China PLA General Hospital
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Amlodipine (`cardio:amlodipine`)

## Provenance

Content hash: 5943cbb6a16255b551adc674b7fd1bf1d05a49d925fd46deb41c4984ea3c0d8e
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
